# Psyence Biomedical Ltd. (PBM)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $3.28 (-1.50%)

> Psyence Biomedical Ltd. is a life science biotechnology company focused on developing botanical, nature-derived psilocybin-based psychedelic medicines for mental health disorders. It specializes in natural psilocybin products aimed at treating psychological trauma, anxiety, depression, adjustment disorder, post-traumatic stress disorder, stress, and grief, particularly in palliative care contexts for patients with incurable cancer diagnoses. The company's lead product candidate, PEX010, is a capsule containing naturally sourced psilocybin under Phase IIb clinical study for psilocybin-assisted psychotherapy. Psyence Biomedical Ltd. operates through an integrated platform encompassing in-house cultivation, manufacturing, and clinical development capabilities. It maintains partnerships, such as with iNGENu Pty Ltd, for advancing clinical trials. As a subsidiary of Psyence Group Inc., it positions itself as a pioneer in evidence-based psychedelic therapeutics targeting unmet needs in palliative care, addiction, and related mental health conditions. Founded in 2021 and headquartered in Toronto, Ontario, Canada, Psyence Biomedical Ltd. plays a role in the emerging field of psychedelic medicine within the biotechnology sector.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/PBM)